FDA Announcement: Recall of Shirakiku Korean Seasoned Seaweed Due to Undeclared Sesame Allergen

Korean Seasoned SeaweedSubmitted Image

WASHINGTON, D.C. — The Food and Drug Administration (FDA) has issued a recall notice for 3.52-ounce packages of Shirakiku brand Korean Seasoned Seaweed, distributed by Wismettac Asian Foods, Inc. based in Santa Fe Springs, California. This recall is prompted by the presence of an undeclared sesame allergen on the product’s outer packaging, posing a significant health risk to individuals with sesame allergies.

Sesame allergies can lead to severe and potentially life-threatening reactions. Symptoms may include hives, swelling, difficulty breathing, and anaphylaxis, requiring immediate medical intervention. It is crucial for individuals with known allergies to avoid consumption of products where allergens are undeclared.

The affected seaweed products were distributed across various states including California, Arizona, Texas, New Mexico, Washington, New York, and Nevada, reaching consumers through retail outlets and restaurants. The products are packaged in illustrated plastic bags weighing 3.52 ounces, each containing five inner packages. While the inner packages correctly list allergens, the outer packaging erroneously omits sesame due to the use of incorrect packing materials. This packaging oversight also resulted in the display of an incorrect UPC code, 074410495534, instead of the correct 074410516031, which is found on the back right side of the outer package.

To date, no illnesses have been reported in association with this recall. The discrepancy was discovered during routine checks that identified undeclared allergens, leading to the immediate cessation of the product’s distribution as of October 8, 2024.

Consumers who have purchased the Shirakiku Korean Seasoned Seaweed are advised to return the product to the point of purchase for a full refund. For further information or assistance, consumers may contact Wismettac Asian Foods, Inc. directly via email at recall@wismettacusa.com.

READ:  FDA Approves Crenessity for Treating Classic Congenital Adrenal Hyperplasia

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.